AAAAAA
Results: 1-25/30
Authors:
Greco, FA
Gray, J
Burris, HA
Erland, JB
Morrissey, LH
Hainsworth, JD
Citation: Fa. Greco et al., Taxane-based chemotherapy for patients with carcinoma of unknown primary site, CANCER J, 7(3), 2001, pp. 203-212
Authors:
Hainsworth, JD
Burris, HA
Calvert, SW
Willcutt, NT
Scullin, DC
Bramham, J
Greco, FA
Citation: Jd. Hainsworth et al., Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network, CANCER INV, 19(4), 2001, pp. 335-339
Authors:
Hainsworth, JD
Burris, HA
Yardley, DA
Bradof, JE
Grimaldi, M
Kalman, LA
Sullivan, T
Baker, M
Erland, JB
Greco, FA
Citation: Jd. Hainsworth et al., Weekly docetaxel in the treatment of elderly patients with advanced breastcancer: A Minnie Pearl Cancer Research Network phase II trial, J CL ONCOL, 19(15), 2001, pp. 3500-3505
Authors:
Meluch, AA
Greco, FA
Burris, HA
O'Rourke, T
Ortega, G
Steis, RG
Morrissey, LH
Johnson, V
Hainsworth, JD
Citation: Aa. Meluch et al., Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl CancerResearch Network, J CL ONCOL, 19(12), 2001, pp. 3018-3024
Authors:
Hainsworth, JD
Burris, HA
Greco, FA
Citation: Jd. Hainsworth et al., Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer, SEMIN ONCOL, 28(3), 2001, pp. 21-25
Authors:
Hainsworth, JD
Burris, HA
Greco, FA
Citation: Jd. Hainsworth et al., Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: A review of the Sarah Cannon Cancer Center Experience, SEMIN ONCOL, 28(2), 2001, pp. 43-47
Authors:
Burris, HA
Citation: Ha. Burris, Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer, SEMIN ONCOL, 28(1), 2001, pp. 38-44
Authors:
Hainsworth, JD
Burris, HA
Billings, FT
Bradof, JE
Baker, M
Greco, FA
Citation: Jd. Hainsworth et al., Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma - Phase II trials of the Minnie Pearl Cancer Research Network, CANCER, 92(9), 2001, pp. 2391-2398
Authors:
Greco, FA
Burris, HA
Gray, JR
Raefsky, EL
Dobbs, C
Smith, S
Rinaldi, D
Morrissey, LH
Erland, JB
Litchy, S
Hainsworth, JD
Citation: Fa. Greco et al., Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy forresected nonsmall cell lung carcinoma - A feasibility study of the Minnie Pearl Cancer Research Network, CANCER, 92(8), 2001, pp. 2142-2147
Authors:
Hainsworth, JD
Burris, HA
Meluch, AA
Baker, MN
Morrissey, LH
Greco, FA
Citation: Jd. Hainsworth et al., Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas - Results of a phase II trial, CANCER, 92(3), 2001, pp. 642-649
Authors:
Hainsworth, JD
Burris, HA
Morrissey, LH
Thomas, M
Erland, JB
Butts, JA
Joseph, G
Kalman, L
Greco, FA
Citation: Jd. Hainsworth et al., Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network, CANCER J, 6(3), 2000, pp. 151-156
Authors:
Greco, FA
Burris, HA
Hainsworth, JD
Citation: Fa. Greco et al., Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer. (vol 14, pg 31, 2000), ONCOLOGY-NY, 14(11), 2000, pp. 1521-1521
Authors:
Burris, HA
Citation: Ha. Burris, Docetaxel (Taxotere) in the treatment of cancer, SEMIN ONCOL, 27(2), 2000, pp. 1-2
Authors:
Burris, HA
Citation: Ha. Burris, Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin), SEMIN ONCOL, 27(2), 2000, pp. 19-23
Authors:
Burris, HA
Hainsworth, JD
Erland, JB
Morrissey, LH
Kalman, LA
Hon, JK
Scullin, DC
Smith, SW
Greco, FA
Citation: Ha. Burris et al., Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer, SEMIN ONCOL, 27(1), 2000, pp. 9-13
Authors:
Hainsworth, JD
Burris, HA
Litchy, S
Morrissey, LH
Barton, JH
Bradof, JE
Greco, FA
Citation: Jd. Hainsworth et al., Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma - A Minnie Pearl Cancer Research Network Phase II trial, CANCER, 89(2), 2000, pp. 328-333
Authors:
Greco, FA
Burris, HA
Erland, JB
Gray, JR
Kalman, LA
Schreeder, MT
Hainsworth, JD
Citation: Fa. Greco et al., Carcinoma of unknown primary site - Long term follow-up after treatment with paclitaxel, carboplatin, and etoposide, CANCER, 89(12), 2000, pp. 2655-2660
Authors:
Hainsworth, JD
Burris, HA
Litchy, S
Erland, JB
Hon, JK
Brierre, JE
Greco, FA
Citation: Jd. Hainsworth et al., Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients - A minnie pearl cancer research network Phase II trial, CANCER, 88(6), 2000, pp. 1353-1358
Authors:
Hainsworth, JD
Burris, HA
Morrissey, LH
Litchy, S
Scullin, DC
Bearden, JD
Richards, P
Greco, FA
Citation: Jd. Hainsworth et al., Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma, BLOOD, 95(10), 2000, pp. 3052-3056
Authors:
Hesketh, PJ
Crowley, JJ
Burris, HA
Williamson, SK
Balcerzak, SP
Peereboom, D
Goodwin, JW
Gross, HM
Moore, DF
Livingston, RB
Gandara, DR
Citation: Pj. Hesketh et al., Evaluation of docetaxel in previously untreated extensive-stage small celllung cancer: A Southwest Oncology Group phase II trial, CA J SCI AM, 5(4), 1999, pp. 237-241
Authors:
Diab, SG
Baker, SD
Joshi, A
Burris, HA
Cobb, PW
Villalona-Calero, RA
Eckhardt, SG
Weiss, GR
Rodriguez, GI
Drengler, R
Kraynak, M
Hammond, L
Finizio, M
Von Hoff, DD
Rowinsky, EK
Citation: Sg. Diab et al., A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors, CLIN CANC R, 5(2), 1999, pp. 299-308
Authors:
Fields-Jones, S
Koletsky, A
Wilding, G
O'Rourke, M
O'Rourke, T
Eckardt, J
Yates, B
McGuirt, C
Burris, HA
Citation: S. Fields-jones et al., Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial, ANN ONCOL, 10(11), 1999, pp. 1307-1310
Authors:
Villalona-Calero, MA
Weiss, GR
Burris, HA
Kraynak, M
Rodrigues, G
Drengler, RL
Eckhardt, SG
Reigner, B
Moczygemba, J
Burger, HU
Griffin, T
Von Hoff, DD
Rowinsky, EK
Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies, J CL ONCOL, 17(6), 1999, pp. 1915-1925
Authors:
Rinaldi, DA
Kuhn, JG
Burris, HA
Dorr, FA
Rodriguez, G
Eckhardt, SG
Jones, S
Woodworth, JR
Baker, S
Langley, C
Mascorro, D
Abrahams, T
Von Hoff, DD
Citation: Da. Rinaldi et al., A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation, CANC CHEMOT, 44(5), 1999, pp. 372-380
Authors:
Pazdur, R
Royce, ME
Rodriguez, GI
Rinaldi, DA
Patt, YZ
Hoff, PM
Burris, HA
Citation: R. Pazdur et al., Phase trial of docetaxel for cholangiocarcinoma, AM J CL ONC, 22(1), 1999, pp. 78-81